— Bio-Path Holdings, Inc. (NASDAQ: BPTH) reported a net loss of $2.2 million or $0.78 share for the third quarter of 2019, vs. $0.74 per share loss expected.
— Research and development expenses decreased to $1.4 million from $2.3 million last year
— General and administrative expenses were $0.9 million during the three-month period, up 29% from last year
— Recorded cash of $15.4 million as of September 30, 2019, compared to $1.0 million at December 31, 2018
— Net cash used in operating activities was $6.1 million during the nine-month period ended September, compared to $4.8 million last year
— Recently, appointed Martina Molsbergen, chief executive officer of C14 Consulting, to the board of directors of Bio-Path
CVS Health Corporation (NYSE: CVS) reported record full-year 2025 consolidated revenues of $402.1 billion, a…
Healthcare solutions company CVS Health Corporation (NYSE: CVS) on Monday reported an increase in revenues…
The industrial materials manufacturer reported flat fourth-quarter sales and a full-year organic growth rate of…
Overview Harley-Davidson, Inc. reported consolidated fourth-quarter 2025 results that point to continued pressure on profitability…
The Coca-Cola Company (NYSE: KO) reported its fourth quarter 2025 earnings results today. Net revenues…
The South Korean telecommunications provider reported a significant increase in annual profit for 2025, supported…